A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer
暂无分享,去创建一个
E. Kohn | E. Winer | W. Barry | M. Birrer | U. Matulonis | Jung-Min Lee | G. Fleming | S. Ivy | Joyce F. Liu | J. Hurteau | M. Buss | B. Rimel | Ronald | W. Luo | C. Whalen | P. Quy | J. Buckanovich | Sreenivasa | Nattam | Lisa Obermayer | H. Lee | Hang Lee